Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
- 解放军医学杂志（英文版） 2021年8卷第3期 页码：433-443
- Affiliations：
Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai 200127, China
- Author bio：
* houjian@medmail.com.cn
- Funds：
DOI：10.1186/s40779-021-00302-x
中图分类号：-
纸质出版：2021-09
- Accepted：
Scan QR Code
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma[J]. 解放军医学杂志（英文版）, 2021,8(3):433-443.
Fang et al.: Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Mil Med Res, 2021, 8: 9.
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma[J]. 解放军医学杂志（英文版）, 2021,8(3):433-443. DOI： 10.1186/s40779-021-00302-x.
Fang et al.: Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Mil Med Res, 2021, 8: 9. DOI： 10.1186/s40779-021-00302-x.
摘要
Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy
and is characterized by the clonal expansion of malignant plasma cells. Despite the recent improvement in patient outcome due to the use of novel therapeutic agents and stem cell transplantation
all patients eventually relapse due to clone evolution. B cell maturation antigen (BCMA) is highly expressed in and specific for MM cells
and has been implicated in the pathogenesis as well as treatment development for MM. In this review
we will summarize representative anti-BCMA immune therapeutic strategies
including BCMA-targeted vaccines
anti-BCMA antibodies and BCMA-targeted CAR cells. Combination of different immunotherapeutic strategies of targeting BCMA
multi-target immune therapeutic strategies
and adding immune modulatory agents to normalize anti-MM immune system in minimal residual disease (MRD) negative patients
will also be discussed.
关键词
Keywords
references
Siegel RL , Miller KD , Jemal A . Cancer statistics . CA Cancer J Clin . 2018 ; 68 ( 1 ): 7 - 30 .
Kumar SK , Dispenzieri A , Lacy MQ , Gertz MA , Buadi FK , Pandey S , et al . Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients . Leukemia . 2014 ; 28 ( 5 ): 1122 - 8 .
Laubach JP , Voorhees PM , Hassoun H , Jakubowiak A , Lonial S , Richardson PG . Current strategies for treatment of relapsed/refractory multiple myeloma . Expert Rev Hematol . 2014 ; 7 ( 1 ): 97 - 111 .
Gonsalves WI , Buadi FK , Ailawadhi S , Bergsagel PL , Chanan Khan AA , Dingli D , et al . Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and riskadapted therapy (mSMART) consensus statement . Bone Marrow Transplant . 2019 ; 54 ( 3 ): 353 - 67 .
Kumar SK , Rajkumar SV . The multiple myelomas - current concepts in cytogenetic classification and therapy . Nat Rev Clin Oncol . 2018 ; 15 ( 7 ): 409 - 21 .
Sanchez E , Tanenbaum EJ , Patil S , Li M , Soof CM , Vidisheva A , et al . The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker . Expert Rev Mol Diagn . 2018 ; 18 ( 4 ): 319 - 29 .
Cohen AD . CAR T cells and other cellular therapies for multiple myeloma: 2018 update . Am Soc Clin Oncol Educ Book . 2018 ; 38 : e6 - e15 .
Tai YT , Anderson KC . Targeting B-cell maturation antigen in multiple myeloma . Immunotherapy . 2015 ; 7 ( 11 ): 1187 - 99 .
Tai YT , Anderson KC . B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma . Expert Opin Biol Ther . 2019 ; 11 : 1 - 14 .
Tai YT , Acharya C , An G , Moschetta M , Zhong MY , Feng X , et al . APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment . Blood . 2016 ; 127 ( 25 ): 3225 - 36 .
Frigyesi I , Adolfsson J , Ali M , Christophersen MK , Johnsson E , Turesson I , et al . Robust isolation of malignant plasma cells in multiple myeloma . Blood . 2014 ; 123 ( 9 ): 1336 - 40 .
Carpenter RO , Evbuomwan MO , Pittaluga S , Rose JJ , Raffeld M , Yang S , et al . B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma . Clin Cancer Res . 2013 ; 19 ( 8 ): 2048 - 60 .
Laurent SA , Hoffmann FS , Kuhn PH , Cheng Q , Chu Y , Schmidt-Supprian M , et al . γ-secretase directly sheds the survival receptor BCMA from plasma cells . Nat Commun . 2015 ; 6 : 7333 .
Sanchez E , Gillespie A , Tang G , Ferros M , Harutyunyan NM , Vardanyan S , et al . Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma . Clin Cancer Res . 2016 ; 22 ( 13 ): 3383 - 97 .
Chen H , Li M , Xu N , Ng N , Sanchez E , Soof CM , et al . Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells . Leuk Res . 2019 ; 81 : 62 - 6 .
Hobo W , Strobbe L , Maas F , Fredrix H , Greupink-Draaisma A , Esendam B , et al . Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and Bcell maturation antigen mRNA for vaccination of multiple myeloma patients . Cancer Immunol Immunother . 2013 ; 62 ( 8 ): 1381 - 92 .
Bae J , Samur M , Richardson P , Munshi NC , Anderson KC . Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy . Leukemia . 2019 ; 33 ( 9 ): 2208 - 26 .
Ryan MC , Hering M , Peckham D , McDonagh CF , Brown L , Kim KM , et al . Antibody targeting of B-cell maturation antigen on malignant plasma cells . Mol Cancer Ther . 2007 ; 6 ( 11 ): 3009 - 18 .
Epps HV , Anderson M , Yu C , Klussman K , Westerdorf L , Carosino C , et al . SEA-BCMA: a highly active enhanced antibody for multiple myeloma . Cancer Res . 2018 ; 78 ( 13 Supplement ): 3833 .
Tai YT , Mayes PA , Acharya C , Zhong MY , Cea M , Cagnetta A , et al . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma . Blood . 2014 ; 123 ( 20 ): 3128 - 38 .
Lee L , Bounds D , Paterson J , Herledan G , Sully K , Seestaller-Wehr LM , et al . Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma . Br J Haematol . 2016 ; 174 ( 6 ): 911 - 22 .
Trudel S , Lendvai N , Popat R , Voorhees PM , Reeves B , Libby EN , et al . Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial . Lancet Oncol . 2018 ; 19 ( 12 ): 1641 - 53 .
Kinneer K , Flynn M , Thomas SB , Meekin J , Varkey R , Xiao X , et al . Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells . Leukemia . 2019 ; 33 ( 3 ): 766 - 71 .
Tai YT , Xing L , Lin L , Yu T , Cho SF , Wen K , et al . MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma . Clin Lymph Myelom Leuk . 2019 ; 19 ( 10 ): e154 - 5 .
Bera TK , Abe Y , Ise T , Oberle A , Gallardo D , Liu XF , et al . Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients . Leukemia . 2018 ; 32 ( 2 ): 569 - 72 .
Shancer Z , Williams M , Igelman A , Nagata S , Ise T , Pastan I , et al . Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma . Antibody Ther . 2018 ; 1 ( 1 ): 19 - 25 .
Thakur A , Huang M , Lum LG . Bispecific antibody based therapeutics: strengths and challenges . Blood Rev . 2018 ; 32 ( 4 ): 339 - 47 .
Seckinger A , Delgado JA , Moser S , Moreno L , Neuber B , Grab A , et al . Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment . Cancer Cell . 2017 ; 31 ( 3 ): 396 - 410 .
Ramadoss NS , Schulman AD , Choi SH , Rodgers DT , Kazane SA , Kim CH , et al . An anti-B cell maturation antigen bispecific antibody for multiple myeloma . J Am Chem Soc . 2015 ; 137 ( 16 ): 5288 - 91 .
Gantke T , Reusch U , Ellwanger K , Fucek I , Weichel M , Treder M . AFM26 - a novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma . Cancer Res . 2017 ; 77 ( 13 Supplement ): 5671 .
Hipp S , Tai YT , Blanset D , Deegen P , Wahl J , Thomas O , et al . A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo . Leukemia . 2017 ; 31 ( 8 ): 1743 - 51 .
Topp MS , Duell J , Zugmaier G , Attal M , Moreau P , Langer C , et al . Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma . J Clin Oncol . 2020 ; 38 ( 8 ): 775 - 83 .
Cho SF , Lin L , Xing L , Wen K , Yu T , Wahl J , et al . AMG 701, a half-life extended anti-BCMA BiTE ® , potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment . Clin Lymph Myelom Leuk . 2019 ; 19 ( 10 ): e54 .
Alhallak K , O’Neal J , Sun J , Muz B , King J , Kohnen D , et al . Nanoparticle multi-specific T cell engagers for the treatment of multiple myeloma . Clin Lymph Myelom Leuk . 2020 ; 8 ( 4 Suppl ): B01 .
Friedman KM , Garrett TE , Evans JW , Horton HM , Latimer HJ , Seidel SL , et al . Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells . Hum Gene Ther . 2018 ; 29 ( 5 ): 585 - 601 .
Raje N , Berdeja J , Lin Y , Siegel D , Jagannath S , Madduri D , et al . Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma . N Engl J Med . 2019 ; 380 ( 18 ): 1726 - 37 .
Berdeja JG , Alsina M , Shah ND , Siegel DS , Jagannath S , Mdduri D , et al . Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy . Blood . 2019 ; 134 ( Supplement_1 ): 927 .
Zhao WH , Liu J , Wang BY , Chen YX , Cao XM , Yang Y , et al . A phase 1, openlabel study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma . J Hematol Oncol . 2018 ; 11 ( 1 ): 141 .
Xu J , Chen LJ , Yang SS , Sun Y , Wu W , Liu YF , et al . Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma . Proc Natl Acad Sci U S A . 2019 ; 116 ( 19 ): 9543 - 51 .
Chen L , Jie X , Fu W , Jin S , Yang S , Yan S , et al . Updated phase 1 results of a first-in-human open-label study of Lcar-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA) . Blood . 2019 ; 134 ( Supplement_1 ): 1858 .
Li C , Wang J , Wang D , Hu G , Yang Y , Zhou X , et al . Efficacy and safety of fully human BCAM targeting CAR T cell therapy in relapsed/refractory multiple myeloma . Blood . 2019 ; 134 ( Supplement_1 ): 929 .
Lin L , Xing L , Cho SF , Wen K , Hsieh P , Kurtoglu M , et al . Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for control of multiple myeloma . Leukemia . 2020 . https://doi.org/10.1038/s41375-020-0951-5 https://doi.org/10.1038/s41375-020-0951-5 .
Sommer C , Boldajipour B , Kuo TC , Bentley T , Sutton J , Chen A , et al . Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma . Mol Ther . 2019 ; 27 ( 6 ): 1126 - 38 .
Paiva B , Puig N , Cedena MT , de Jong BG , Ruiz Y , Rapado I , et al . Differentiation stage of myeloma plasma cells: biological and clinical significance . Leukemia . 2017 ; 31 ( 2 ): 382 - 92 .
Garfall AL , Maus MV , Hwang WT , Lacey SF , Mahnke YD , Melenhorst JJ , et al . Chimeric antigen receptor T cells against CD19 for multiple myeloma . N Engl J Med . 2015 ; 373 ( 11 ): 1040 - 7 .
Yan Z , Cao J , Cheng H , Qiao J , Zhang H , Wang Y , et al . A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial . Lancet Haematol . 2019 ; 6 ( 10 ): e521 - 9 .
Li C , Mei H , Hu Y , Guo T , Liu L , Jiang H , et al . A bispecific CAR-T cell therapy targeting BCAM and CD38 for relapsed/refractory multiple myeloma: Updated results from a phase 1 dose-climbing trial . Blood . 2019 ; 134 ( Supplement_1 ): 930 .
Zhang H , Gao L , Liu L , Wang J , Wang S , Gao L , et al . A Bcma and CD19 bispecific CAR-T for relapse and refractory multiple myeloma . Blood . 2019 ; 134 ( Supplement_1 ): 3147 .
Chen KH , Wada M , Pinz KG , Liu H , Shuai X , Chen X , et al . A compound chimeric antigen receptor strategy for targeting multiple myeloma . Leukemia . 2018 ; 32 ( 2 ): 402 - 12 .
Lonial S , Dimopoulos M , Palumbo A , White D , Grosicki S , Spicka I , et al . Elotuzumab therapy for relapsed or refractory multiple myeloma . N Engl J Med . 2015 ; 373 ( 7 ): 621 - 31 .
Chu J , Deng Y , Benson DM , He S , Hughes T , Zhang J , et al . CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma . Leukemia . 2014 ; 28 ( 4 ): 917 - 27 .
Lee L , Draper B , Chaplin N , Philip B , Chin M , Galas-Filipowicz D , et al . An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma . Blood . 2018 ; 131 ( 7 ): 746 - 58 .
Schmidts A , Ormhøj M , Choi BD , Taylor AO , Bouffard AA , Scarfò I , et al . Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma . Blood Adv . 2019 ; 3 ( 21 ): 3248 - 60 .
O’Neal J , Ritchey J , Cooper M , Niswonger J , Gonzalez S , Lee BH , et al . In vivo efficacy of BCMA-iNKT-CAR is enhanced by NT-I7, a long-acting IL-7 . Clin Lymph Myelom Leuk . 2019 ; 19 ( 10 ): e25 .
Waki K , Kawano K , Tsuda N , Ushijima K , Itoh K , Yamada A . Plasma levels of high-mobility group box 1 during peptide vaccination in patients with recurrent ovarian cancer . J Immunol Res . 2017 ; 2017 : 1423683 .
Sakamoto S , Yamada T , Terazaki Y , Yoshiyama K , Sugawara S , Takamori S , et al . Feasibility study of personalized peptide vaccination for advanced small cell lung cancer . Clin Lung Cancer . 2017 ; 18 ( 6 ): e385 - 94 .
Cohen AD . Myeloma: next generation immunotherapy . Hematol Am Soc Hematol Educ Program . 2019 ; 2019 ( 1 ): 266 - 72 .
Sidana S , Shah N . CAR T-cell therapy: is it prime time in myeloma? Blood Adv . 2019 ; 3 ( 21 ): 3473 - 80 .
Hamieh M , Dobrin A , Cabriolu A , van der Stegen SJC , Giavridis T , Mansilla-Soto J , et al . CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape . Nature . 2019 ; 568 ( 7750 ): 112 - 6 .
Ledergor G , McCarthy E , Shah N , Wong S , Chang H , Fan F , et al . Single cell dissection of resistance to anti-BCMA CAR-T cell therapy . Clin Lymph Myelom Leuk . 2019 ; 19 ( 10 suppl ): e25 - e26 .
Pont MJ , Hill T , Cole GO , Abbott JJ , Kelliher J , Salter AI , et al . γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma . Blood . 2019 ; 134 ( 19 ): 1585 - 97 .
0
浏览量
0
Downloads
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies